U.S. Markets open in 6 hrs 27 mins
  • S&P Futures

    3,993.00
    -26.75 (-0.67%)
     
  • Dow Futures

    31,960.00
    -160.00 (-0.50%)
     
  • Nasdaq Futures

    12,285.75
    -97.00 (-0.78%)
     
  • Russell 2000 Futures

    1,776.20
    -13.30 (-0.74%)
     
  • Crude Oil

    109.51
    -0.98 (-0.89%)
     
  • Gold

    1,803.90
    -4.30 (-0.24%)
     
  • Silver

    21.00
    -0.00 (-0.00%)
     
  • EUR/USD

    1.0408
    -0.0009 (-0.0833%)
     
  • 10-Yr Bond

    2.9350
    0.0000 (0.00%)
     
  • Vix

    28.87
    -2.90 (-9.13%)
     
  • GBP/USD

    1.2225
    -0.0037 (-0.3032%)
     
  • USD/JPY

    128.8360
    -0.3490 (-0.2702%)
     
  • BTC-USD

    29,536.78
    -332.83 (-1.11%)
     
  • CMC Crypto 200

    662.13
    -18.97 (-2.79%)
     
  • FTSE 100

    7,418.15
    0.00 (0.00%)
     
  • Nikkei 225

    26,547.05
    +119.40 (+0.45%)
     

Nabriva Therapeutics to Present at the 20th Annual Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

DUBLIN, Ireland and KING OF PRUSSIA, Pa., April 01, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that Ted Schroeder, Chief Executive Offer at Nabriva, will provide a company overview and business update at the 20th Annual Needham Virtual Healthcare Conference on Thursday, April 15, at 2:15p.m. ET.

The presentation may be accessed by visiting the "Investors" section of the Company's website under the "Events and Presentations" tab at www.nabriva.com.

About Nabriva Therapeutics plc

Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections. Nabriva Therapeutics received U.S. Food and Drug Administration approval for XENLETA® (lefamulin), the first pleuromutilin antibiotic for community-acquired bacterial pneumonia (CABP). Nabriva Therapeutics is also developing CONTEPO™ (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTIs), including acute pyelonephritis. Nabriva entered into an exclusive agreement with subsidiaries of Merck & Co. Inc., Kenilworth, N.J., USA to market, sell and distribute SIVEXTRO® (tedizolid phosphate) in the United States and certain of its territories. For more information, please visit https://www.nabriva.com

CONTACTS:

For Investors
Kim Anderson
Nabriva Therapeutics plc
IR@Nabriva.com

For Media
Mike Beyer
Sam Brown Inc.
mikebeyer@sambrown.com
312-961-2502